Zio AT ECG Monitoring System vs ElucidVivo A.3

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 60/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Zio AT ECG Monitoring System

by iRhythm Technologies, Inc.

ElucidVivo A.3

by Elucid

AI Verdict

Tool A, the Zio AT ECG Monitoring System, is designed for continuous, AI-powered ECG monitoring to detect arrhythmias using a wearable patch. Conversely, Tool B, ElucidVivo A.3, specializes in AI-powered quantitative analysis of arterial plaque composition from CT angiography for atherosclerosis patient stratification. While both are FDA-cleared cardiology AI tools, they address distinct aspects of cardiovascular health using different data modalities and serve complementary rather than directly competitive clinical needs.

Choose Zio AT ECG Monitoring System if…

Choose Zio AT if you need continuous, long-term monitoring for suspected cardiac arrhythmias that may be intermittent or asymptomatic. This system is ideal for detecting a wide range of cardiac events over an extended period, providing real-time data transmission and AI-powered analysis for comprehensive diagnostic insights.

View Zio AT ECG Monitoring System →

Choose ElucidVivo A.3 if…

Choose ElucidVivo A.3 if you require detailed, quantitative analysis of arterial plaque composition and stability from CT angiography. This tool is best suited for stratifying patients with atherosclerosis, aiding in risk assessment, and optimizing treatment decisions based on precise visualization and measurement of plaque characteristics.

View ElucidVivo A.3 →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Zio AT ECG Monitoring System	ElucidVivo A.3
Pricing	Contact for pricing	Unknown
Deployment	Cloud-based (data analytics and clinician portal)	Cloud and on-premise secure deployment.
BAA Available	Yes AI-estimated	Unknown
FDA Status	Cleared AI-estimated	Cleared AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Zio AT ECG Monitoring System

Tool A offers a broader and more direct focus on patient usability through its wearable patch and dedicated patient app, alongside a clinician portal and mobile app for comprehensive management. Tool B's usability is primarily clinician-focused, integrating into existing imaging workflows.

Clinical Value

Tie

Both tools provide significant and distinct clinical value in different areas of cardiology. Tool A excels in long-term arrhythmia diagnosis through continuous ECG monitoring, while Tool B offers advanced, quantitative insights into atherosclerosis by analyzing plaque composition and stability, both addressing critical clinical needs.

Pricing & Value

Tie

Both tools have opaque pricing models, requiring direct contact for quotes. Without publicly available pricing details or comparative cost-effectiveness studies, it is not possible to determine which offers better financial value.

Enterprise Readiness

Zio AT ECG Monitoring System

Tool A explicitly states its HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption. While Tool B's compliance is implied by its intended use in healthcare, Tool A provides clear, documented assurances.

Innovation

ElucidVivo A.3

While both are innovative, Tool B's ability to provide detailed, quantitative, and histologically validated analysis of arterial plaque composition, including the derivation of fractional flow reserve (FFRct), represents a more profound advancement in diagnostic capability for atherosclerosis. Tool A's innovation lies in its long-term, patient-friendly cardiac rhythm monitoring with AI.

Support & Docs

Zio AT ECG Monitoring System

iRhythm Technologies (Tool A) offers extensive patient and provider support, including 24/7 phone and email assistance, along with publicly available FAQs and comprehensive instructions for use. In contrast, specific details regarding Tool B's support channels, service level agreements, or a comprehensive public document library are not explicitly outlined in the available information.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Zio AT ECG Monitoring System	ElucidVivo A.3
Name	Zio AT ECG Monitoring System	ElucidVivo A.3
Company	iRhythm Technologies, Inc.	Elucid Bioimaging
Primary Function	Continuous, AI-powered ECG monitoring for long-term arrhythmia detection and comprehensive reporting.	AI-powered medical image analysis for quantitative analysis of arterial plaque composition and stability from CT angiography.
Categories	Cardiology AI, Wearables & Remote Monitoring (RPM)	Cardiology AI, Radiology & Imaging AI
Specialties	Cardiology	Cardiology, Radiology, Vascular Surgery
Key Features (Summary)	Wearable Zio AT patch for continuous ECG recording, wireless gateway for real-time data, FDA-cleared deep-learned AI algorithm for arrhythmia detection, comprehensive end-of-wear reports, clinician and patient mobile apps.	AI-powered quantitative analysis of arterial plaque (LRNC, matrix, calcifications), visualization of lesion-level plaque composition, 3D visualization of highlighted vessels, aids in stratifying patients with atherosclerosis, derives fractional flow reserve (FFRct).

Videos

Demos, reviews, and walkthroughs featuring Zio AT ECG Monitoring System and ElucidVivo A.3.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do Zio AT and ElucidVivo A.3 integrate with existing clinical workflows and EHR systems to minimize disruption and maximize efficiency?

Zio AT integrates through its ZioSuite clinician portal and mobile app for patient management and report interpretation, with seamless EHR integration to simplify data collection and entry. ElucidVivo A.3, as a software application, is designed to integrate with PACS/EMR systems for seamless image transfer, analysis, and reporting of arterial plaque characteristics within radiology and cardiology workflows.

For which specific patient populations or clinical scenarios does each tool offer the most significant diagnostic or treatment decision-making advantages?

Zio AT is primarily beneficial for patients requiring long-term, continuous ECG monitoring to detect symptomatic and asymptomatic cardiac arrhythmias over up to 14 days, particularly for conditions like atrial fibrillation. ElucidVivo A.3 aids in atherosclerosis patient stratification and optimizes treatment decisions by providing quantitative analysis of arterial plaque composition from CT angiography, especially useful in cardiology, radiology, and vascular surgery for assessing plaque stability and risk.

What is the level of accuracy and clinical validation for the AI-powered analysis provided by each system?

Zio AT utilizes an FDA-cleared deep-learned AI algorithm (ZEUS System) for arrhythmia detection, offering continuous and uninterrupted ECG recording with 99% physician agreement on end-of-wear reports. ElucidVivo A.3 provides AI-powered quantitative analysis of arterial plaque composition, with its measurements of Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications validated against ground-truth histology, demonstrating high accuracy.

What is the expected learning curve for physicians and staff, and how quickly can a practice realize the clinical and operational benefits of each tool?

For Zio AT, the learning curve involves familiarization with the wearable patch application, wireless gateway, and the ZioSuite portal for report interpretation, with studies suggesting reduced staff burden and accelerated patient care pathways. For ElucidVivo A.3, the learning curve focuses on interpreting detailed quantitative plaque analysis and 3D visualizations within existing imaging workflows, aiming for rapid integration into clinical decision-making to optimize treatment.

What are the key considerations for implementing and managing each system across multiple clinical sites or a larger healthcare network?

For Zio AT, multi-site rollout involves standardizing patient onboarding, device distribution, and centralized report review through the ZioSuite portal, with integration options like Epic Aura streamlining workflows. For ElucidVivo A.3, multi-site deployment focuses on consistent integration with PACS/EMR systems across different locations and uniform access to the software application for image analysis, ensuring consistent performance and data access.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring Zio AT ECG Monitoring System or ElucidVivo A.3

Backers

Who funded each tool's parent company.